Cargando…
EDP-938, a novel nucleoprotein inhibitor of respiratory syncytial virus, demonstrates potent antiviral activities in vitro and in a non-human primate model
EDP-938 is a novel non-fusion replication inhibitor of respiratory syncytial virus (RSV). It is highly active against all RSV-A and B laboratory strains and clinical isolates tested in vitro in various cell lines and assays, with half-maximal effective concentrations (EC(50)s) of 21, 23 and 64 nM ag...
Autores principales: | Rhodin, Michael H. J., McAllister, Nicole V., Castillo, Jonathan, Noton, Sarah L., Fearns, Rachel, Kim, In Jong, Yu, Jianming, Blaisdell, Thomas P., Panarese, Joseph, Shook, Brian C., Or, Yat Sun, Goodwin, Bryan, Lin, Kai |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7993833/ https://www.ncbi.nlm.nih.gov/pubmed/33720995 http://dx.doi.org/10.1371/journal.ppat.1009428 |
Ejemplares similares
-
667. Preclinical Pharmacokinetic and Pharmacodynamic Characterization of EDP-938, a Novel and Potent NonFusion Replication Inhibitor of Respiratory Syncytial Virus
por: Jiang, Li-Juan, et al.
Publicado: (2019) -
923. EDP-938, A Respiratory Syncytial Virus (RSV) antiviral, demonstrates a high barrier to resistance in a human challenge study
por: Levene, Rachel E, et al.
Publicado: (2023) -
EDP-938, un nuevo antiviral con actividad inhibidora frente a la nucleoproteína del virus respiratorio sincitial
por: Reina, Jordi, et al.
Publicado: (2022) -
LB6. EDP-938, a Novel RSV N-Inhibitor, Administered Once or Twice Daily Was Safe and Demonstrated Robust Antiviral and Clinical Efficacy in a Healthy Volunteer Challenge Study
por: Coakley, Eoin, et al.
Publicado: (2019) -
Killing two birds with one stone: How the respiratory syncytial virus polymerase initiates transcription and replication
por: Noton, Sarah L., et al.
Publicado: (2019)